Alevin is delighted to announce that it has won the Best Biotech Startup Company at the renowned OBN Awards 2022.
This accolade recognises Alevin’s commitment to using targeted integrin treatments to produce novel small molecule RGD integrin inhibitors with superior drug-like qualities. The discovery-stage compounds have broad therapeutic applications in areas of high unmet clinical need – fibrosis, kidney disease, and cancer – with the most advanced asset being an inhaled drug for the treatment of idiopathic pulmonary fibrosis.
The life sciences industry's most prestigious and sought-after awards programme, the OBN Awards was created to recognise and honour innovation and exceptional success in all facets of the sector.
Sunil Shah, Executive Chair of Alevin said “It was a great honour to pick up this award on behalf of all my colleagues in Alevin Therapeutics: Thomas McInally, Chris Moody, Alison John and Alice MacGowan. We are a team that are working closely together to build our RGD Integrin platform with a focus on our earlier oncology and our more advanced inhaled IPF programmes. We plan to be a clinical stage biotechnology company by 2024. Thank you to OBN for this award that recognises the potential of this team and company.”